

re review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44(5):745-755.

9. Bortnick E, Brown C, Simma-Chiang V, et al. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol. 2020;12:1-11.

10. Halawani A, Paterson R, Zhong T, et al. Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate Int. 2024;12(2):57-64.

11. Marenčák J. Čo je nové vo farmakoterapii benígnej hyperplázie prostaty. Klin Farmakol Farm. 2023;37(1):10-18.

12. Oelke M, Wagg A, Takita Y, et al. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men > 75 years: integrated analysis of pooled data from multinational, randomized, placebo-controlled clinical studies. BJU Int. 2017;119(5):793-803.

13. Sinha S, Cameron A, Tse V, et al. Storage-dominant lower urinary tract symptoms in the older male: practical approach, guidelines recommendations and limitations of evidence. Continence. 2024;11:101320.

14. Lerner L, McVary K, Barry M, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline Part I-Initial work-up and medical management. J Urol. 2021;206(4):806-817.

15. Franco J, Trivisonno L, Sgarbossa N, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023;6(6):CD001423.

16. Franco J, Tesolin P, Jung J. Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures. Prostate Int. 2023;11(1):1-7.

17. Lotterstäter M, Sekleher S, Wimpissinger F, et al. Transurethral resection of the prostate in 85+ patients: a retrospective, multicenter study. World J urol. 2022;40(12):3015-3020.

18. Hartung F, Kowalewski K, von Hardenberg J, et al. Holmium versus thulium laser enucleation of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus. 2022;8(2):545-554.

19. Nottingham C, Large T, Agarwal D, et al. Comparison of newly optimized Moses technology versus standard holmium:YAG for endoscopic laser enucleation of the prostate. J Endourol. 2021;35(9):1393-1399.

20. Bouhadana D, Bguyen D, Zhang X, et al. Safety and efficacy of TURP vs laser prostatectomy for the treatment of benign prostatic hyperplasia in multi-morbid and elderly individuals aged ≥ 75. World J Urol. 2021;39(12):4405-4412.

21. Yim A, Alberto M, Yan X, et al. Comparing Greenlight PVP and HoLEP beyond 5 years: a systematic review of long-term functional outcomes and reoperative rates. BJU Compass. 2025;6(2):e483.

22. Chen D, Qu I, Webb L, et al. Aquablation in men with benign prostatic hyperplasia: a systematic review and meta-analysis. Curr Urol. 2023;17(1):68-76.

23. Gangwish D, Jabeer M, Kennedy A, et al. Aquablation compared with simple prostatectomy for prostate volumes > 80 grams. J Endourol. 2025 Feb 21; doi: 10.1089/end.2024.0583. Online ahead of print.

24. Roehrborn C, Barkin J, Gange S, et al. Five year results of the prospective randomized controlled prostatic urethral lift study. Can J Urol. 2017;24(3):8802-8814.

25. Shah B, Tayon K, Madiraju S, et al. Prostatic urethral lift: does size matter? J Endourol. 2018;32(7):635-638.

26. Lehner K, Popat S, Utech K, et al. Outcomes of prostatic urethral lift in a medically complex population at a veterans affairs hospital. BJU Compass. 2022;3(3):214-219.

27. Knight L, Dale M, Cleves A, et al. Urolift for treating lower urinary tract symptoms of benign prostatic hyperplasia: a NICE medical technology guidance update. Appl Health Econ Health Policy. 2022;20(5):669-680.

Econ Health Policy. 2022;20(5):669-680.

28. Babar M, Loloi J, Tang K, et al. Emerging outcomes of water vapor thermal therapy (Rezūm) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. Low Urin Tract Symptoms. 2022;14(3):140-154.

29. Bassily D, Wong V, Phillips J, et al. Rezūm for retention – retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia. Prostate. 2021;81(14):1049-1054.

30. Bhatia S, Sinha V, Kava B, et al. Efficacy of prostatic artery embolization for catheter-dependent patients with large prostate sizes and high comorbidity scores. J Vasc Interv Radiol. 2018;29(1):78-84.

31. Bagla S, Singh I, Sajan A, et al. Combination prostatic artery embolization prior to water-jet ablation (Aquablation) for benign prostatic hypertrophy: a propensity score analysis. J Clin Med. 2024;13(22):6930. doi: 10.3390/jcm13226930.

32. Chughtai B, Elterman D, Shore N, et al. The ITind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, randomized, controlled trial. Urology. 2021;153:270-276.

33. Kaplan S, Moss J, Freedman S. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE study). Prostate Cancer Prostatic Dis. 2024;27(3):531-536.

34. Pichardo M, Rijo E, Espino G, et al. Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study. World J Urol. 2023;41(8):2209-2215.

35. Fourmarier M, Baboudjian M, Robert G, et al. Is there a best timing for benign prostatic hyperplasia surgery? Fr J Urol. 2024;34(2):102574.

28. ročník Moravského urologického sympozia



Aktuální informace sledujte na
www.kongresurologie.cz

18.–19. 5. 2026
Hotel Sepetná

MÍSTO KONÁNÍ
Hotel Sepetná
Ostravice, www.sepetna.cz

